Keyword: Actavis

Thanks to groundwork laid by the feds, UnitedHealthcare is suing dozens of generics companies for alleged price fixing—and it wants its money back.

Rebel investors earlier this month called for changes at Allergan, and now the company has appointed a new director.

Sarepta CEO Douglas Ingram may have netted biopharma's biggest 2017 compensation package after six months on the job.

Rita Luthra, M.D., was convicted Monday in a Warner marketing scheme—and in more evidence that it's the cover-up that gets you, for lying to investigators.

Endo, Teva and a Japanese drugmaker have agreed to fork over more than $270 million to resolve a class-action suit over Lidoderm.

Kroger and other grocery chains are suing Mylan, Teva, Endo and many other companies for an "overarching conspiracy" to artificially inflate prices.

Valeant and Pershing Square are one step closer to putting years of insider trading allegations in the past.

Valeant will pay $96.25 million and Pershing Square will pay $193.75 million to settle insider trading allegations.

Ahead of an expected merger, the combined company of Amneal-plus-Impax has a new CEO.

Valeant and former activist partner Bill Ackman may once again be thwarted in their efforts to get insider trading claims against them tossed.